BioCryst Pharmaceuticals Profile

5.94
USD 0.12  1.98%
39%
0%

Bona fide gift to Featheringill William W of 60000 shares of BioCryst Pharmaceuticals subject to Section 16

BioCryst Pharmaceuticals insider trading alert for gift of common stock by Featheringill William W, the corporate stakeholder, on July 15, 2018. This event was filed by Biocryst Pharmaceuticals with SEC on 2006-12-05. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

BioCryst Pharmaceuticals Summary

BioCryst Pharmaceuticals (BCRX) is traded on BATS Exchange in USA. It is located in NORTH CAROLINA U.S.A and employs 85 people. BioCryst Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 627.84 M. BioCryst Pharmaceuticals conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 98.72 M outstanding shares of which 10.31 M shares are currently shorted by private and institutional investors with about 11.8 trading days to cover. BIOCRYST PHARM IN currently holds about 91.31 M in cash with (18.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.93.
Check BioCryst Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 5.94HorizonTargetOdds Above 5.94
49.01%30 days 5.94 50.67%
Based on normal probability distribution, the odds of BioCryst Pharmaceuticals to move above current price in 30 days from now is about 50.67% (This BioCryst Pharmaceuticals probability density function shows the probability of BioCryst Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Franklin Street Advisors IncCommon Shares43 K246 K
Amalgamated BankCommon Shares14.8 K85 K
View BioCryst Pharmaceuticals Diagnostics

Selected BioCryst Pharmaceuticals Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

BioCryst Pharmaceuticals Against Markets

Current Ratings

BioCryst Pharmaceuticals 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
5 
Chance of
Financial Distress (0 to 100%)
47 
Equity ratings for BioCryst Pharmaceuticals are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. BioCryst Pharmaceuticals operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 85 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
BioCryst Pharmaceuticals SEC Filings
BioCryst Pharmaceuticals SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameBioCryst Pharmaceuticals
CEOJon StonehouseView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
LocationNORTH CAROLINA U.S.A
Business Address4505 Emperor Boulevard
ExchangeBATS Exchange
CIK Number0000882796
CUSIP09058V103
SectorHealthcare
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.biocryst.com
Phone919 859 1302
CurrencyUSD - US Dollar

BioCryst Pharmaceuticals Corporate Directors

Fred Cohen Director
Stanley Erck Independent Director
Robert Ingram Director
Check also Trending Equities. Please also try Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
vendors/bower_components/jquery.easy-pie-chart/dist/jquery.easypiechart.min.js">